Explain this page
Arphra AIPlain-English read on Johnson & Johnson’s valuation06-03today
- Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.15h
- How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)18h
- The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar21h
- The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I'm Loading Up on Anyway1d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$293.76
+21.96% vs spot
Recommendation
Buy
18 of 19 methods
Method spread
4bull12bear
±5% threshold
Analyst PT consensus: $249.27 (+3.49%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.00% | +4.66% | +7.34% | -0.55% | +13.77% | +16.31% | +53.65% | +50.54% | +45.56% | +106.10% | +19630.33% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$30.69M
10 txns
Net flow
−$30.69M
Aftermarket
LiveLast trade
$240.58
Bid
$238.50
200 sh
Ask
$240.90
400 sh
Spread
$2.400
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $24.06B | $5.24B | $2.14 |
| Q4 Dec 2025 | $24.56B | $5.12B | $2.10 |
| Q3 Sep 2025 | $23.99B | $5.15B | $2.12 |
| Q2 Jun 2025 | $23.74B | $5.54B | $2.29 |
| Q1 Mar 2025 | $21.89B | $11B | $4.54 |
| Q4 Dec 2024 | $22.52B | $3.43B | $1.41 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$249.27
+3.49% upside
Low
$208.00
Median
$250.00
High
$283.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.fool.com·Jun 12, 2026
- How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)247wallst.com·Jun 12, 2026
- The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar247wallst.com·Jun 12, 2026
- The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I'm Loading Up on Anyway247wallst.com·Jun 11, 2026
- 3 No-Brainer Dividend Growth Stocks to Buy in June247wallst.com·Jun 11, 2026
- Johnson & Johnson Eyes Rare Disease Expansiongurufocus.com·Jun 11, 2026
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patientsgurufocus.com·Jun 11, 2026
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patientsbusinesswire.com·Jun 11, 2026
Peers
Total assets
$199.21B
Total debt
$47.93B
Cash & equiv
$19.71B
Operating CF
$24.53B
Free cash flow
$19.7B
Buybacks
-$5.95B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Decker Robert J officer: VP Corporate Controller | Sell | 4,075 | $1.01M | Feb 27, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 1,322 | $324.76K | Feb 20, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 13,625 | $3.33M | Feb 18, 2026 |
Schmid Timothy officer: EVP, WW Chair, MedTech | Sell | 8,998 | $2.2M | Feb 18, 2026 |
REED JOHN C officer: EVP, Innovative Medicine, R&D | Sell | 2,283 | $554.77K | Feb 17, 2026 |
Wolk Joseph J officer: Exec VP, CFO | Sell | 24,961 | $6.06M | Feb 17, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $94.19B | $25.6B | $26.8B | $11.03 | +28.46% |
| FY 2024 | $88.82B | $22.15B | $14.07B | $5.79 | +15.84% |
| FY 2023 | $85.16B | $23.41B | $35.15B | $13.72 | +41.28% |
| FY 2023 | $79.99B | $21.01B | $17.94B | $6.73 | +22.43% |
| FY 2022 | $78.74B | $20.94B | $20.88B | $7.81 | +26.52% |